A Phase 2, Randomized, 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary) ; Degarelix (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 05 Apr 2019 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
- 05 Apr 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.